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INTRODUCTION AND OBJECTIVE OF THE INVESTIGATION
Novel drug delivery systems, are being employed both experimentally 
and  therapeutically  to  alter  the  body distribution  of  drugs  with  a  view to 
reduce the toxicity of existing drugs and delivering them more efficiently. One 
such area in which research is gaining much attention is “controlled drug 
delivery”  because  of  their  more  precise,  reduced  toxicity  and  enhanced 
efficacy.
It  has  been  reported  that  about  40%  of  the  compounds  being 
developed by the pharmaceutical industry are poorly water-soluble. A limiting 
factor  to  the  in vivo performance of  poorly  water-soluble  drugs after  oral 
administration is their inadequate ability to be wetter and dissolved into the 
fluid in the gastrointestinal (GI) tract. Therefore increasing the dissolution rate 
of  poorly  soluble  drugs  is  an  important  and  significant  challenge  to 
pharmaceutical scientists, in order to maximize absorption 1.
Microspheres has more advantages over  other  soluble carriers like 
liposomes. Liposomes have low efficiency of drug entrapment, rapid leakage 
of water soluble drugs, especially in the presence of blood components, poor 
storage stability and method of preparation; which are poorly compatible with 
large  scale  production  requirements.  However  microspheres  can  entrap 
various molecules in a stable and reproducible way.
Griseofulvin is an antifungal drug widely used for the treatment of the 
dermatophytoses.  Because of  the emergence of  more effective  antifungal 
drugs,  Griseofulvin  use  reduced  today.  The  physicochemical  property  of 
Griseofulvin as a lipophilic molecule which is practically insoluble in water 
makes formulation and delivery difficult.
However, this molecule still interests researchers. It was proven that 
Griseofulvin  dissolution  rate  could  be  enhanced  by  micronization, 
complexation of Griseofulvn with cyclodextrin 2.
The main purpose of this piece of study was to compare the different 
character  of  Griseofulvin  microsphere  using  two  methods  with  different 
polymers Chitosan and Ethylcellulose. Chitosan is a natural polymer and the 
method adopted for preparing microsphere is chemical cross-linking method. 
Ethylcellulose is a natural, biodegradable polymer and the method adopted 
for preparing microsphere is solvent evaporation method.
The plan of work was desingned into different stages;-
 Preparation of Chitosan and Ethylcellulose microspheres using 
thermal  cross  linking  and  solvent  evaporation  methods 
respectively.
 Determination of size and shape of microspheres.
 Estimation of percentage yield of the microspheres and its drug 
encapsulation efficiency.
 Study of in vitro release from prepared microspheres.
 
1. INTRODUCTION 3,4,5
Drugs were there, are there will be there till there is life on this planet. 
However over the years we have learnt that optimization of drug therapy is of 
paramount  importance  and  in  the  process;  patient  safety,  convenience, 
compliance, economic and industrial feasibility are also to be overlooked.
For decades an acute and chronic illness is being clinically treated 
through delivery of drug to patients in form of some conventional  dosage 
forms.  Moreover  these conventional  dosage forms need repetitive  dosing 
with small dosing intervals thus causing inconvenience to patients.
In  the  recent  years,  researchers  developed  newer  drug  delivery 
systems having more precise, spatial and temporal placement of drug in the 
body through a controlled drug delivery.
Basically there are 3 basic modes of drug delivery that  is targeted 
delivery, controlled, and modulated release. Targeted delivery refers to the 
systemic administration of drug carrier with the goal of delivering the drug to 
specific cell types, tissues, and organs. Controlled release refers to the use 
of delivery device with  the objective of releasing the drug into the patient 
body at a predominant rate  at a specific time or with specific release profiles. 
Modulated release implies of drug delivery device that release the drug at a 
variable rate controlled by environmental conditions, bio feed back, sensor 
input or an external control device.
1.1. Definition
Controlled drug delivery system is one, which delivers the drug at a 
predetermined rate locally or systemically for a period of time.
Controlled release dosage forms have been referred to by a number 
of terminologies, such as delayed-action, extended-action, gradual-release, 
prolonged-release, depot, repeated-action, slow-release, sustained-release, 
retard  and  timed-release  dosage  forms.  Any  of  these  terms,  or  similar 
labeling for designation of controlled release dosage forms.
Fig: 1
Objective of controlled delivery
 Get an extended duration of action, thus increase patient compliance.
 Localize drug action by spatial or controlled release system adjacent 
to or in the diseased tissue or organ.   
 Targeted drug action by using carriers or chemical derivatization to 
deliver drugs to a particular target cell type. 
1.2. Advantages
1) Decrease adverse effects and toxicity
2) Better drug utilization.
3) Controlled rate and site of release.
4) More uniform blood concentration.
5) Improved patient compliance.
6) Reduced dosing frequency.
7) More consistent and prolonged therapeutic effect.
8) A greater selectivity of pharmacological activity.
9) Avoidance of night time dosing.
1.3. Disadvantages
1) Increased variability among dosage units.
2) Stability problems.
3) Toxicity due to dose dumping.
4) Increase cost.
5) More rapid development of tolerance.
6) Need for additional patient education and counseling.
7) Poor in vitro and in vivo correlation.
8) Decreased systemic availability.
9) Retrieval of drug is difficult in case of toxicity of hypersensitivity 
reactions.
1.4. Factors governing the design of controlled release dosage form:-
Drug related
- Aqueous solubilityPartition coefficient
- Molecular size
- Drug stability
- Protein binding
Biological factors:
- Absorption.
- Cardiac rhythm.
- Distribution.
- Elimination.
- Duration of action.
- Margin of safety.
- Side effects.
- Disease state.
Physiological
- Prolonged drug absorption.
- Variability in GI emptying and motility.
- GI blood flow
Pharmacological
- Changes in drug effect upon multiple dosing.
- Sensitizing / tolerance.
Pharmacokinetic
- Dose dumping.
- First pass metabolism.
- Variability of urinary pH effect on elimination.
- Enzyme induction/ inhibition upon multiple dosing.
1.5. Classification of oral controlled release systems:
A) Continuous release systems
1. Dissolution controlled release systems
a) Matrix type b) Reservoir type
2. Diffusion controlled release systems
a) Matrix type b) Reservoir type
3. Dissolution  and  diffusion  controlled  release 
systems
4. Ion exchange resin drug complexes
5. Slow dissolving salts and complexes
6. Osmotic pressure controlled systems
7. pH dependent formulations
8. Hydrodynamic pressure controlled systems
B) Delayed transit and continuous release systems
1. Altered density systems
a. High density
b. Low density
c. Floating
2. Mucoadhesive systems
3. Size based systems
C) Delayed release systems
1. Intestinal release systems
2. Colonic release systems
1.6. Future directions in controlled drug delivery
The most exciting opportunities in controlled drug delivery lies in the 
area of responsive delivery systems, with which it will be possible to deliver 
drugs through implantable devices in response to a measured blood level or 
to delivery a drug precisely to a targeted site.  Much of the developments of 
novel materials in controlled drug delivery is focusing on the preparation and 
use of the responsive polymers with  specifically defined macroscopic and 
microscopic structural and chemical features.
Such systems include,
• Copolymers with desirable hydrophilic / hydrophobic interactions 
• Block or graft copolymers
• Complexation networks responding via hydrogen or ionic bonding
• Dendrimers or  star  polymers  as  nanoparticles  for  immobilization  of 
enzymes, drugs, peptides or other biological agents.
1.7. MICROENCAPSULATION
Microencapsulation is one of the most intriguing fields in the area of drug delivery 
systems, moreover this method used to produce controlled release dosage forms. It  is a 
technology  devoted  to  entrapping  solid,  liquids  or  gels  inside  one  or  more  polymeric 
coatings. Depending on the manufacturing process, various types of microcapsules structure 
can be obtained. The most common type is the mononuclear spherical. The microcapsulate 
drug  delivery  systems  include  mainly  pellets,  microcapsules,  microspheres,  liposomes, 
emulsions and multiple emulsions. The size range covered by the microparticle is between 1 
to 1000 µm.
Classification of Microencapsulation methods:
Table:1
Process Coating material Solvent
Interfacial 
polymerization
Water soluble and 
insoluble monomer
Aqueous or organic 
solvent
Complex 
coacervation
Water-soluble 
polyelectrolyte Organic solvent
Coacervation Hydrophobic polymers Organic solvent
Thermal 
denaturation Proteins Organic
Salting out Water-soluble polymers Water
Solvent evaporation Hydrophilic or 
hydrophobic polymers
Organic or water
Hot melt Hydrophilic or hydrophobic polymers
Aqueous or organic 
solvent
Solvent removal Hydrophilic or hydrophobic polymers Organic solvent
Spray drying Hydrophilic or hydrophobic polymers Air, nitrogen
Phase separation Hydrophilic or hydrophobic polymers Aqueous or organic
(i) Reasons for microencapsulation 
- Taste and odor masking
- Conversion of oils and other liquids into solids for ease 
of 
 handling
- Protection of drug against the environment
- Delay of volatilization
- Separation of flow of powders
- Safe handling of toxic substances
- Isolation from tissues
- Enteric coating 
- Sustained  and controlled release
- Detoxification
(ii)  Properties of Drugs used for  Microencapsulation
The core of microcapsules used in medicine contains one or more drugs 
either alone or in combinations with suitable additives to form a liquid or solid 
phase.  Liquid  core  may be composed of  polar  or  non polar  substantial  that 
comprises the active ingredient or that act as vehicle for dissolved or suspended 
drugs. The solvent properties of such  liquids will critically influences the rate of 
drug release and  the  selection  of  coating  materials.  For  drugs of  low water 
solubility  with  known  bioavailability  problems  associated  with  low  rates  of 
dissolution, decreases in particle size of suspended drugs may be important in 
enhanceing  in  vivo absorption.  Smaller  Microcapsules to  have faster  release 
rates because of their increased surface area per unit volume or weight of core 
material. Solid cores are used more frequently than liquid cores. Very small core 
particles tend to give aggregation problem during production, because of their 
surface  attraction  forces.  Large  particles  can  cause  problems  of  their  rapid 
sedimentation.
The shape of these cores also important, It is much easier to deposite 
uniform  coating  on  regular  spherical  particles  of  narrow size  range  that  are 
devoid of sharp edges. Accordingly,  choice of particular polymorphs of drugs, 
reduction of irregular  shaped crystalline material  by grinding or use of  spray 
drying forms. Density of cores very important in controlled the transit time in  GI 
tract. Increasing density was the most factore promoteing, retention of pellets in 
stomach.
Ex: High density systems.
Decreaseing density is important in floating type dosage forms. Swelling of core 
with disruption of coating and leads to  un controlled drug release.
(iii)  Properties of Polymer used for Microencapsulation
          The selection of the appropriate coating materials dictates, to a major  
degree the resultant physical and chemical properties of the Microcapsules. The 
coating material should be capable of forming a film that cohesive with the core 
material and the ideal coating material should be chemically compatible and non 
reactive with core material, and provide the desired coating properties such as 
strength, flexibility, impermeability, optical properties and stability.
          Typical coating properties such as cohesiveness, permeability, moisture  
sorption, solubility,  stability and clarity must be considered in the selection of 
proper coating material. The uniqueness of Microcapsules in their properties and 
use involves their characteristic smallness.
          Consequently, the protective coating that are applied are quite thin. 
Although the active content of many Microcapsulated products can be varied 
from a few percent to over 99%, the effective coating thickness that can be 
realized, regardless of the method of application employed varies from tenths 
to few hundred microns, depending on the coating to core ratio and the 
particle size (surface area) of the core material.
1.8. MICROSPHERES AND MICROCAPSULES
Microspheres can be defined as spherical empty particles ranging in 
size  from  1  to  1000  micrometer.  Microspheres  are  characteristically  free 
flowing  powder  consisting  of  proteins  or  synthetic  polymers,  which  are 
biodegradable in nature.
Microcapsules is system consists of a well-defined core and a well-
defined envelope; the core can be solid, liquid or gas, the envelop is made of 
continuous process or nonporous polymeric phase. 
It is also defined as a spherical particle with size varying from 50nm to 
2mm containing a core substance. 
        
(b)
Fig:2 various configurations of (a) microcapsules and (b) microspheres 
Microspheres have been investigated for intravenous and intra arterial 
targeting and delivery systems. Microspheres and microcapsule have been 
injected in the vessels to ensure the passive targeting of drugs. The drug 
release  is  controlled  by  diffusion  through  the  polymer  matrix  and/or  by 
erosion of the polymer. The role of microspheres and microcapsules depend 
their size and site of injection.
Microparticles  of  diameter  smaller  than 2μm can be injected in  an 
intravenous, intra arterial and intra peritoneal manner in order to target the 
RES. Intravenous injection of microspheres of size from 3-12 micrometer is 
intended to block the capillaries of lungs, liver and spleen.
Vessels  can  be  hyperselectively  embolized  with  drug  loaded 
particulate materials of more than 10 micrometer. Microspheres of 100-300 
micrometer size are the most appropriate embolic agents. They reach the 
intra lesional precapillary arteries and cause reduction of blood flow.
Drugs can be incorporated in microsphere and microcapsule by two 
methods:
1. The  polymer  can  either  surround a  core  of  drug (encapsulated 
type).
2. The drug can be dissolved or  homogeneously  dispersed in  the 
polymer (matrix device – microsphere type).
(i)  The advantages of microspheres
1. Taste and odor masking.
2. Conversion of oils and other liquids to solids for ease of handling.
3. Protection of drugs against the environment (moisture, light, heat, 
and/or oxidation) and vice versa (prevention of pain on injection).
4. Delay of volatilization.
5. Separation  of  incompatible  materials  (other  drugs  or  excipients 
such as buffers).
6. Improvement of flow of powders.
7. Safe handling of toxic substances.
8. Aid in dispersion of water-insoluble substances in aqueous media.
9. Production of sustained-release, controlled-release, and targeted 
medications.
(ii) Route of administration:
Route of administration is selected depending on the drug properties, 
disease  state  being  treated  and  the  age  and  condition  of  the  patient. 
Desirable properties of the microspheres to be used for the delivery will also 
change depending on the route of administration.
a) Oral delivery:
Oral delivery is the simplest way of drug administration. Constraints of the oral route 
are numerous on the whole  it  offers less potential  danger than the parentral  route.  The 
relatively brief transit time of about 12hours trough the GI tract limits the duration of action 
that can be expected via the oral route. Recently, it has been reported that microsphers of 
less than 10µm in size are taken up by the Peyer’s patches and may increase the retention 
time in the stomach. Also microsphere made from polymers with mucoadhesive propertied 
get attached to the stomach and prolong the residence time in the stomach. Bioavailability of 
drugs with limited solubility in the stomach or intestine and small absorption rate constant 
can be increasing by increasing the retention time in the stomach. Improved drug delivery 
was observed compared to the microspheres administered alone.
b) Parenteral delivery:
Most of the microspheres based controlled delivery systems are developed with the 
aim of using them for parenteral administration. Drug released is completely absorbed in this 
case. Microspheres used for parenteral delivery should be sterile and should be dispersible 
in a suitable vehicle for injection. Surfactants in small concentration are often necessary for 
reconstituting hydrophobic particles for injection in aqueous vehicles, which are reported to,  
came adverse tissue reactions and affect the release of the incorporated drug.
(iii)  Polymers used:
Synthetic polymers
Non-biodegradale:
PMMA
Acrolein
Glycidyl methacrylate
Epoxy polymers
Biodegradable:
Lactides and Glycolides
Polyalkyl cyano acrylates
Polyanhydrides
Natural materials
Proteins:
Albumin
Gelatin
Collagen
Carbohydrates:
Starch
Agarose
Carrageenan
Chitosan
Chemically modified carbohydrates:
DEAE cellulose
Poly( acryl dextran)
Poly( acryl) starch
 
Prerequisites for an ideal microparticulate carriers
• Longer duration of action
• Control of content release
• Increase of therapeutic efficiency
• Protection of drug
• Reduction of toxicity
• Biocompatability
• Sterilizability
• Relative stability
• Water solubility or dispersability
• Bioresorbability
• Targetability
• Polyvalent
(iv) Methods of preparation:
The method of preparation and its choice are equicocally determined 
by some formulation and technology related factors as mentioned below:
1. The particle size requirement
2. The drug or the protein should not be adversely affected by the 
process
3. Reproducibility of the release profile and the method 
4. No stability problem
5. There should be no toxic products associated with the final product
Synthetic polymers are now materials of choice for the controlled release as well as 
targeted micro particulate carriers. The various methods are described below.
Solvent evaporation
A technique is based on the evaporation of the initially phase of an 
emulsion by agitation. Initially, the polymeric supporting material is dissolved 
in a volatile organic solvent. The active principle to be encapsulated is then 
dispersed  of  dissolved  in  the  organic  solution  to  form  a  suspension, 
emulsion, or solution. In the following step the organic phase is emulsified 
under  agitation  in  a  dispersing  phase  consisting  of  a  non  solvent  of  the 
polymer,  which  is  immiscible  with  the  organic  solvent,  which  contains  an 
appropriate tension active additive. Once emulsion is stablilized, agitation is 
maintained  and  solvent  is  the  creation  of  solid  microspheres.  On  the 
completion  of  the  solvent  evaporation  process,  the  microspheres  held  in 
suspension  in  the  continuous  phase  are  recovered  by  filtration  of 
centrifugation and are washed and dried.
1. Thermal and Chemical cross linking:
Micro spheres made from natural polymers are prepared by a cross 
linking process; the polymers include gelatin albumin, starch and dextran. A 
water oil emulsion is prepared, where the water phase is a solution of the 
polymer,  which  contains  the  drug to  be  incorporated.  The oil  phase is  a 
suitable vegetable oil or oil-organic solvent mixture containing an oil-soluble 
emulsifier. Once the desired water-oil emulsion is formed, the water-soluble 
polymer is solidified by some kind of cross-linking process. This may involve 
thermal  treatment  or  the  addition  of  a  chemical  cross-  linking  agent  like 
Glutaraldehyde. In the chemical and thermal cross linking both the amount of 
chemical and intensity of heating are critical in determining the release rates 
and swelling properties of the micro spheres. If  the Glutaraldehyde is the 
cross linking agent, residual amounts can have toxic effects.
Precipitation
A variation on the evaporation method is the precipitation method. The 
emulsion consists of polar droplets dispersed in a no polar medium. Solvent 
may be removed from the droplets by the use of a co solvent. The resulting 
increase in the polymer-drug concentration causes a precipitation forming a 
suspension.
2. Freeze drying
This  technique  involves  the  freezing  of  the  emulsion;  the  relative 
freezing points of the continuous and dispersed phases are important. The 
continuous-phase solvent is usually organic and is removed by sublimation at 
low temperature and pressure. Finally,  the dispersed-phase solvent of the 
droplets is removed by sublimation, leaving polymer-drug particles.
3. Spray drying and spray congealing
Spray drying and spray congealing methods are based on the drying 
of the mist of the polymer and drug in the air. Depending upon the removal of 
the solvent or the cooling of the solution, the two processes are named spray 
drying and the spray congealing respectively. 
The polymer  is  first  dissolved in  a  suitable  volatile  organic solvent 
such as dichloromethane, acetone, etc. The drug in the solid form is then 
dispersed in the polymer  solution under  high-speed homogenization.  This 
dispersion is then atomized in a stream of hot air. The atomization leads to 
the formation of the small droplets or the fine mist from which the solvent 
evaporates instantaneously leading the formation of  the microsphers in  a 
size range 1-100µm. Microparticles are separated from the hot air by means 
of the cyclone separator while the traces of solvent are removed by vaccum 
drying.
Very  rapid  solvent  evaporation,  however  leads  to  the  formation  of 
porous microparticles.
Advantages:
1. Feasibility of the operation under aseptic conditions.
2. The process is rapid.
3. Suitable for both batch and bulk manufacturing.
4. This technique is used to encapsulate a large number of drugs.
6.  Phase separation coaservation techniques
Phase  separation  method  is  specially  designed  for  preparing  the 
reservoir  type of the system, i.e.  to  encapsulate water  soluble drugs e.g. 
peptides,  proteins,  however,  some of  the  preparations are  of  matrix  type 
particularly, when the drug is hydrophobic in nature e.g. steroids. In matrix 
type device, the drug or the protein is soluble in the polymer phase. The 
process is based on the principle of decreasing the solubility of the polymer 
in the organic phase to affect the formation of the polymer rich phase called 
the coacervates. The coacervation can be brought about by addition of the 
third  component  to  the  system which  results  in  the  formation  of  the  two 
phase, one rich in the polymer, while other one, i.e. supernatant, depleted of 
the polymer. This is achieved by the addition of salt, non-solvent addition, 
addition of the incompatible polymer or change in pH.
In this technique, the polymer is first dissolved in a suitable solvent 
and then drug is dispersed by making its aqueous solution. Phase separation 
is then accomplished by changing the solution conditions by using any of the 
method  mentioned  above.  The  process  is  carried  out  under  continuous 
stirring to control the size of the microparticles. 
(v)  Loading of drug:
The active components are loaded over the microspheres principally 
using two methods, i.e., during preparation of the microsphere or after the 
formation of the microspheres by incubation them with the drug/protein. The 
active  component  can  be  loaded  by  means  of  the  physical  entrapment, 
chemical linkage and surface absorption.
Maximum loading can be achieved by incorporating the drug during 
the  time  of  preparation  but  it  may  get  affected  by  many  other  process 
variables such as method of preparation, presence of additives ( eg: cross-
linking agent,  surfactants, stabilizers etc),  heat of polymerization, agitation 
intensity  etc.  The  loading  is  carried  out  in  pre-formed  microspheres  by 
incubating them with high concentration of the drug in a suitable solvent. The 
drug in these microspheres is loaded via penetration of diffusion of the drug 
through the pores in the microspheres as well as adsorption on their surface. 
The solvent is then removed, leaving drug loaded microsphere.
The Freundlich  model  is  applied  to  determine  the  adsorption  of  the  drugs.  The 
Frenudlich equation is,
X
M
=KC
Peq
Where,  
K = Constant related to the capacity of the adsorbent for the 
adsorbate.
P = Constant related to the affinity of the adsorbent for the 
adsorbate.
(vi) Release of drug form the micro spheres
The rate of drug release form micro spheres dictates their therapeutic 
action. Drug release is governed by the molecular structure of the drug and 
polymer the resistance of the polymer to degradation and the surface area 
and porosity of the micro spheres.
Reservoir delivery systems extend the residence time of drug within 
the systemic circulation originally focused on zero-order dissolution kinetics.
In porous polymeric systems the rate of drug release is dictated by the 
device surface area, which is linked directly to its shape. The rate of release 
form spheres may result from polymer diffusion or erosion.
The  internal  structure  may  vary  as  a  function  of  the  microencapsulation 
process employed. Reservoir microcapsules have a core of drug coated with 
polymer.  The drug is distributed homogeneously throughout the polymeric 
matrix in monolithic micro spheres.
The  mechanism  of  drug  release  at  a  controlled  rate  from  micro 
spheres include diffusion of drug through a polymeric excipient, diffusion of 
trapped drug as polymer erodes, and release of drug through pores in the 
polymeric excipient.
Increase the surface area, by reducing the particle size, results in an 
increased release rate. The path length travel by the drug in the matrix can 
be controlled by manipulating the micro sphere loading. Micro spheres with 
high drug content release the outline ingredient more rapidly than those with 
a low load. Thicknesses of the polymer also influence the drug release rate. 
Mechanism of drug release:
Factors affecting the release of the drug form the particulate system in 
relation to drug, microspheres and bioenvironment.
Drug:
Position in microspheres
Molecular weight
Concentration
Interaction with matrix
Microspheres:
Type and amount of the matrix polymer
Size and density of the microspheres
Extent of cross linking, denaturation or polymerization
Adjuvants
Environment:
PH
Polarity
Presence of Enzyme
The geometry of the carrier, ie, whether it is reservoir type where the 
drug  is  present  as  a  core,  or  matrix  type  in  which  drug  is  dispersed 
throughout the carrier, governs overall release profile of the drug or active 
ingredients.
Reservoir type system
Release  from  the  reservoir  type  system  with  rate  controlling 
membrane proceeds by first penetration of the water through the membrane 
followed by dissolution of the drug in the penetrating dissolution fluid. The 
dissolved drug after partitioning through the membrane diffuses across the 
stagnant diffusion layer.  The release is essentially governed by the Fick’s 
first law of diffusion as,
         J = - D (dc/dx)
Where, 
J = flux per unit area
D= diffusion coefficient
Diffusion across the membrane determines the effectiveness of the 
carrier  system.  The  release  rate  from  the  carriers  can  be  modified  by 
changing  both  the  composition  and  the  thickness  of  the  polymeric 
membrane.
Matrix type system
Release  profile  of  the  drug  form  this  type  of  the  device  critically 
depends on the state of  drug whether  it  is  dissolved or  dispersed in  the 
polymer matrix.
In case of the drug dissolved in the polymeric matrix, amount of drug, 
and the nature of the polymer affect the release profile. If this is the case the 
amount of drug appearing in the receptor phase at ‘t’ is approximated by two 
separate  equations.  The  first  equation  determines  the  60%  of  the  drug 
release while the second shows the release profile at later stage.
dM t
dt
=2MX D / πl
2 t 
1
2
dM t
dt
=8DM X /l
2 exp π 2Dt / l
2
 Where,
l      =  thickness of polymer slab
D    =  diffusion coefficient
Mx  =  total amount of drug present in the matrix
Mt   =  amount of drug released in time ‘t’ 
When the drug is dispersed throughout the polymer matrix then the 
release profile follows Higuchi’s equation.
dM t
dt
= A
2
2DC sCo 
Where,
A   = area of matrix
Cs = solubility of the drug in matrix
Co = total concentration in the matrix
(vii)  Fate of microsphere in the body
Table:2 Proposed mechanism for uptake of microspheres
 (viii)  Applications of microsphers
- Microspheres in vaccine delivery
- Antigen release
- Immune system
- Targeting  using  micro  particulate  carriers  (ocular, 
intranasal, oral)
- Magnetic microspheres
- Monoclonal  antibodies  mediated  microspheres 
targeting immunomicrospheres
- Imaging
- Micro sponges: topical porous microspheres.
1.9.  Chitosan Microspheres
 Chitosan react with controlled amounts of multivalent anion result in 
cross inking between chitosan molecules. The cross linking may be achieved 
in acidic,  neutral  or  basic environment depending on the method applied. 
This cross linking has been extensively used for the preparation of chitosan 
microspheres.  The  process  that  have  been  used  for  the  preparation  of 
chitosan  microspheres  are  given  below.  Down  outlines  various  methods 
which have been used for the preparation of chitosan microspheres.
Fig: 3 Schematic representation of various methods of preparation of 
chitosan microspheres.
(i) Thermal and chemical cross linking
Microspheres made from natural polymers are prepared by a cross 
linking process; the polymers include gelatin albumin, starch and dextran. A 
water oil emulsion is prepared, where the water phase is a solution of the 
polymer,  which  contains  the  drug to  be  incorporated.  The oil  phase is  a 
suitable vegetable oil or oil-organic solvent mixture containing an oil-soluble 
emulsifier. Once the desired water-oil emulsion is formed, the water-soluble 
polymer is solidified by some kind of cross-linking process. This may involve 
thermal  treatment  or  the  addition  of  a  chemical  cross-  linking  agent  like 
Glutaraldehyde. In the chemical and thermal cross linking both the amount of 
chemical and intensity of heating are critical in determining the release rates 
and swelling properties of the micro spheres. If  the Glutaraldehyde is the 
cross linking agent, residual amounts can have toxic effects.
1.10. Ethyl cellulose Microspheres
Ethyl cellulose microsphere were prepared based on the principle of 
coacervation with certain modifications, the rational for selecting EC for the 
shell material was that this substance is commonly used as an additive to 
foods  and  drug  because  of  its  high  inertness,  and  forms  a  stable, 
semipermeable capsular membrane.
Ethyl  cellulose  is  synthetic  polymer,  synthetic  polymers  have  the 
advantage that they can be easily and reproducibly prepared. This can be 
copolymerized  with  one  another  to  alter  their  physical,  chemical  and 
mechanical properties and can be prepared as low or high molecular weight 
material  by  suitable  reaction  conditions.  Chemical  bonds  which  are 
susceptible  to  degradation  include  amides,  esters,  orthoesters,  acetyls, 
glycosides and related groups. Biodegradability of the polymer depends on 
many factors such as polymer structure, molecular weight, physical form of 
the polymer  and environment in which the polymer  is  placed since many 
Proteolytic enzymes specifically catalyzes the hydrolyses of peptide linkages 
adjacent  to  substituted  proteins,  substituted  polymers  containing  benzyl, 
hydroxyl, carboxy-methyl and phenyl groups have been prepared to improve 
biodegradability
(i) Solvent evaporation process
Solvent evaporation technique was fully developed at the end of the 
1990s since them numerous studies have been carried out on the basis of 
this method.
A technique is based on the evaporation of the initially phase of an 
emulsion by agitation. Initially, the polymeric supporting material is dissolved 
in a volatile organic solvent. The active principle to be encapsulated is then 
dispersed  of  dissolved  in  the  organic  solution  to  form  a  suspension, 
emulsion, or solution. In the following step the organic phase is emulsified 
under  agitation  a  dispersing  phase  consisting  of  a  non  solvent  of  the 
polymer,  which  is  immiscible  with  the  organic  solvent,  which  contains  an 
appropriate tension active additive. Once emulsion is stabilized, agitation is 
maintained  and  solvent  is  the  creation  of  solid  microspheres.  On  the 
completion  of  the  solvent  evaporation  process,  the  microspheres  held  in 
suspension  in  the  continuous  phase  are  recovered  by  filtration  of 
centrifugation and are washed and dried.
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GRISEOFULVIN
Chemistry
Griseofulvin  is  (2S,4R)-7-chloro-2,4,6-trimethoxy  -4-methylspiro-
[benzofuran-2(3H),3-cyclohexane]-3,6-dione,  produced  by  the  growth  of 
certain strains of Penicillium griseofulvin or obtained by any other means. It is 
heterocyclic bezofuran).
Category
Antifungal
Description
White to yellowish white powder, the particles of which are generally 
up  to  5  µm in  maximum dimension,  although  larger  particles  which  may 
occasionally exceed 30 µm may be present; almost odorless.
Molecular weight
352.77
Empirical formula:
 C17H17ClO6 
O
O
OCH3
H3CO
O OCH3
CH3
Solubility  
 Freely soluble in dimethylformamide and In 1,1,2,2-tetrachloroethane ; 
soluble in acetone and in chloroform ; slightly soluble in ethanol(95%) and in 
methanol ; practically insoluble in water.
Storage  
Stored in tightly closed containers.
Pharmacodynamics
Mechanism of action 
Griseofulvin  exerts  its  fungistatic  action  primarily  by  disrupting  the 
cells miotic spindle structure, thus arresting the metaphase of cell division. 
Although  the  effect  on  mitosis  is  similar  to  that  caused  by  colchicine,  a 
different mechanism is probably involved. Another proposed mechanism of 
action  is  that  griseofulvin  causes  production  of  defective  DNA  which  is 
unable to replicate.
Pharmacokinetics
Absorption 
Following oral administration griseofulvin is absorbed principally from 
the  duodenum.  Absorption  of  microsize  griseofulvin  is  variable  and 
unpredicatable  and  range  from  25-70%  of  an  oral  dose.  Absorption 
enhanced by administration of drug with fatty meals.
Ultramicrosize  griseofulvin  is  almost  completely  absorbed  following 
oral  administration.  A  single  500mg  dose  of  griseofulvin  administered  to 
fasting adults produces mean peak serum concentration of 0.5-2 mcg/ml 4 
hours after oral administration.
  
Half life  
10 – 30 hours
Distribution  
Following absorption  griseofulvin  is  concentrated  in  skin,  nail,  hair, 
liver, fat, and skeletal muscles. Griseofulvin is deposited in keratin precursor 
cells and has a high affinity for diseased, tissue; the drug is tightly bound to 
new keratin.
Within  4  hours  after  administration  of  a  single  500mg  dose  of 
microsize griseofulvin, concentration of 1 mcg/gm of skin have been found ; 
after 8 hours of the dose 3 mcg/gm found in the skin.
Griseofulvin concentrations in skin are higher in warm climates than in 
cold.
Elimination  
Griseofulvin has an elimination half life of 9-24 hours.
Griseofulvin  is  oxidatively  demethylated  and  conjugated  with 
glucuronic  acid,  principally  in  the  liver.  The  major  metabolites,  6-
desmethylgriseofulvin, is microbiologically inactive which is excreted in urine. 
A  large  amount  of  dose  of  griseofulvin  of  reduced  particle  size  appears 
unchanged  in the faeces; less than 1% is excreted unchanged in the urine; 
some is excreted in the sweat.
Spectrum of activity 
In vitro griseofulvin concentrations of 0.15-0.5 mcg/ml inhibit species 
of  Trichophyton,  Microsporum and Epidermophyton when they are exposed 
to  the  drug  for  72  hours.  Specifically,  griseofulvin  is  active  against 
Microsporum  andouinni,  M.canis,  M.gypseum and  Epidermophyton 
floccosum,  Trichophyton  rubrum,  T.eonsurans,  T.mentagrophytes,  
T.megninii, T.gallinae and T.schoenleinni.
Antimicrobial action  
Griseofulvin is fungistatic antibiotic which inhibits fungal cell division 
by disruption of the mitotic spindle structure. It may also interfere with DNA 
production.  It  is  active  against  dermatophytes,  including  some species  of 
Epidermophyton, Microsporum or Trichophyton.
Drug interaction 
Phenobarbitone has been reported  to  decrease the  gastrointestinal 
absorption of griseofulvin.
Griseofulvin may increase the rate of metabolism and effects of some 
drugs such as coumarin anticoagulants and oral contraceptives.
Griseofulvin has also been reported to reduce plasma concentration of 
salicyliate in a patient taking aspirin.
Griseofulvin may enhance the effect of alcohol.
Precautions 
Griseofulvin is contra-indicated in patients with porphyria, liver failure, 
or systemic lupus erythematosus.
Griseofulvin is contra indicated in pregnancy.
Griseofulvin may reduce the effectiveness of oral contraceptives.
Griseofulvin may impair the ability to drive or operate machinery, and 
has been reported to enhance the effects of alcohol.
Griseofulvin has been associated with acute attack of porphyria and is 
considered cusate in patients with acute porphyria.
Adverse effects:
Side effects are usually mild and transient and consist of headache, 
skin rashes, dryness of the mouth, and altered sensation of taste, and gastro 
intestinal disturbances.
Depression,  confusion,  dizziness,  insomnia  and  fatigue  have  also 
been reported.
There  have  been  a  few  reports  of  hepatotoxicity  attributed  to 
griseofulvin.
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In the present study Chitosan and Ethyl  cellulose were used in the 
preparation of micropartilces.
(i) CHITOSAN:
(ά – (1,4)2-amino-2-deoxy-β-D glucan ) is a polysaccharide derived 
from chitin.
Source:
Chitin  ,  a  polysaccharide  of  animal  origin  is  obtained  from  waste 
material of crustaceans such as crabs, lobsters, hrimps, prawns and crayfish. 
Also from the exo-skeleton and wings of insects crustacean shells.
Molecular Weight:
1-3 x105 Da
O
H
HH
H
OH
H NH3
+
CH2OH
O
CH3
O
CH3
n
Physical Characters:
It occurs as odorless, white or creamy-white powder or flakes. Fiber 
formation is quite common during precipitation and the chitosan may look 
cotton like.
Chemical Characters:
Chitosan is a cationic polyamine with a high charge density at pH <6.5 
so adheres to negatively charged surface and chelates metal ions. It  is a 
linear polyelectrolyte with ractive hydeoxyl and amino groups so available for 
chemical reaction and salt formation.numerous studies have demonstrated 
that the salt form, molecular weight, and degreee of deacetylation as well as 
pH at which the chitosan is used all influence how this polymer is utilized in 
pharmaceutical application.
Solubility:
Chitin is insoluble in most of the solvent, acids and bases, chitosan is 
insoluble in  neutral   and alkaline pH values but  dissolves in  organic and 
inorganic  acids  (e.g.  acetic  acid,  formic  acid,  glutamic  acid,  lactic  acid. 
hydrochloric acid etc.) to produce viscous polyelectrolyte  solution.         
Preparation of chitosan from chitin:
Crustacean  shells  are  the  usual  raw  material  of  chitin.  Shells  are 
cleaned of all adhering flesh and washed with water. These are crushed into 
small pieces and dried and ground to fine powder. It is cleaned from proteins 
and lipids by treatment for 3 hours in 1N sodium hydroxide solution and for 
12 hours in 1N hydrochloride acid solution at room temperature to remove 
calcium carbonate. The alkali  and acid treatments are repeated twice, the 
chitin is decolourised by refluxing in acetone.
Toxicity:
Chitosan  caused  concentration  dependent  toxicity  towards  cells  in 
vitro and red blood cell lysis. It has similar structural characteristic as that of  
glycosamino glycans. It is tough, biodegradable and non-toxic. In vivo toxicity 
test  indicated  that  chitosan  is  non-toxic,  inert-LD 50  oral  toxicity  level  of 
chitosan  were  established  both  in  mice  and  rats.  Lack  of  chitosan  was 
noticed as evidenced by an oral LD 50.10 g/ Kg. in mice. Acute systemic 
toxicity tests in mice did not show any toxic effects of chitosan. Eye irritation 
in rabbits and skin irritation test in guinea pig did not reveal any undesirable 
toxic effects of chitosan. All the pharmacological test were undertaken as per 
USP.
Chitosan is cheap, widely available in Indian coastal areas giving wide 
opportunities  to  drug  development  professionally  for  better  drug  delivery 
system.
Applications
1. It  is  used for variety of  biomedical  applications including wound 
dressing and drug delivery system.
2. It is used for making absorbable and digestible surgical sutures.
3. Chitin and Chitosan are used as vehicle in compressed tablets.
4. It has been used as direct compression diluent.
5. It is an agent for the enhancement of the dissolution properties of 
some less soluble drugs.
6. Chitosan has acid-lowering effect of the stomach.
7. Chitosan is forming gel at low pH and has antacid and antiulcer 
activities that may prevent of reduce drug irritation in the stomach. 
(ii) ETHYLCELLULOSE:
Synonyms:
Aquacoat ECD, aqualon E 462, ethocel, surelease.
Chemical name:
Cellulose ethyl ether
Description:
Ethyl cellulose is a tasteless, free flowing, white to light tan-coloured 
powder.
Density:
0.4 g/cm3
Glass transition temperature:
129 – 133º C
Solubility:
Ethyl  cellulose  is  practically  insoluble  in  glycerin,  propylene  glycol, 
water.
Ethyl cellulose that contains less than 46.5% of ethoxy groups is freely 
soluble  in  chloroform.  Methyl  acetate,  tetrahydrofuran,  aromatic 
hydrocarbons and ethanol.
Freely soluble in ethanol, ethylacetate, methanol, toluene.
O
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Specific gravity:
1.12 – 1.15 g/cm3
Viscosity:
5 – 100m pascals ( 7 – 100cp)
Functional category
Coating agent, flavouring fixative, tablet binder, tablet filler, viscocity-
increasing agent.
Method of manufacture
Ethyl cellulose is prepared by treating purified cellulose (sourced from 
chemical-grade  cotton,  linters  and  wood  pulp)  with  an  alkaline  solution, 
followed by ethylation of the alkali.  Cellulose with  chloroethane as shown 
below, where R represents the cellulose radical.
The manner ethyl group is added to cellulose can be described by the 
degree  of  substitution(DS).  The  DS  designates  the  average  number  of 
hydroxyl positions on the anhydroglucose unit that have been reacted with 
ethyl chloride. Since each anhydroglucose unit of the cellulose molecule has 
three hydroxyl groups, the maximum value for DS is 3.
Stability and storage conditions
Ethylcellulose  is  stable,  slightly  hygroscopic  material.  Chemically 
resistant  to  alkali,  more  sensitive  to  acidic  materials.  Ethyl  cellulose  is 
subjected to oxidative degradation in the presence of sunlight or UV light at 
elevated  temperature.  This  may be  prevented  by  use  of  antioxidant  and 
chemical additives that absorb light in the 230-340nm range.
It should be stored at a temperature not exceeding 32ºC in a day area 
away from all sources of heat. It should not be stored next to peroxides or 
other oxidizing agents.
Safety
Ethyl  cellulose  widely  used  in  oral  and  topical  pharmaceutical 
formulations.  It  is  also  used  in  food  products.  Ethyl  cellulose  is  not 
metabolized  following  oral  consumption  and  is  therefore  a  noncalorific 
substance.  Because  ethyl  cellulose  is  not  meatabolized  it  is  not 
recommended for parenteral products; parenteral use may be harmful to the 
kidneys.
Ethyl  cellulose generally  regarded as a nontoxic  nonallergenic and 
non irritating material.  An ethyl  cellulose is not considered to be a health 
hazard; the WHO has not specified an acceptable daily intake.
Incompatabilities:
With paraffin wax and microcrystalline wax.
Applications in pharmaceutical formulations:
1) hydrophobic coating agent for tablets and granules.
2) Modified the release of drug.
3) To mask the unpleasant taste of drug.
4) To improve the stability of formulation.
5) Thickness agent in creams, lotions, gels.
6) Used in cosmetics, food products.
7) Binder in tablets.
II. REVIEW OF LITERATURE
1. Akbuga et al.,12 (1999) prepared Chitosan microspheres containing cis-
platin  using  a  w/o  emulsion  system.  Variables  important  for 
microsphere properties were investigated: these include; chitosan, cis-
platin and glutaraldehyde concentration, the types of chitosan and oil, 
cross linking process and stirring rate. Chitosan and glutaraldehyde 
concentrations, the type of oil and chitosan have a significant effect on 
cis-platin entrapment in chitosan microspheres. Cis-platin release from 
microspheres is characterized by an initial burst effect.
2. Denkbas  et  al.,13(1999)  prepared  Chitosan  microspheres  by  a 
suspension  cross-linking  technique.  A  petroleum  ether/mineral  oil 
mixture  was  used  as  the  suspension  medium  which  includes  an 
emulsifier,  e.g.  Tween-80.  Glutaraldehyde  was  used  as  the  cross-
linker.5-Fluorocuacil  was incorporated in the matrix  for  the possible 
use of the microspheres in chemoembolization. Smaller microspheres 
with  narrower  size  distributions  were  obtained  when  the 
chitosan/solvent ratio and drug/chitosan ratio were lower.
3. Tamilvanan  et  al.,14(2000)  prepared  Ibuprofen-loaded  polystyrene 
microparticles by the emulsion-solvent  evaporation process from an 
aqueous system. The drug content  in  all  the formulations was less 
than the theoretical drug loading. The lower drug content was due to 
drug partitioning to  the  external  aqueous phase during formulation. 
The  effect  of  size  of  the  micropaticles  in  drug  release  was  more 
important for the low drug-loaded microparticles than that for the high 
drug-loaded  microparticles.  Such  release  behavior  from  the 
microparticles  was  explained  on  the  basis  of  the  morphological 
structure of the microparticles.
4. Lin  et  al.,15(2000)  prepared  water-soluble  sodium diclofenac-loaded 
microspheres with three low-molecular weight polyesters, poly(L-lactic 
acid)(PLA),  copoly(lactic  acid/glycolic  acid)(PLGA)  and  poly(δ-
valerolactone)(PV),  using  the  oil-in-oil(o/o)  emulsification-solvent 
evaporation  method.  The  results  indicate  that  high  encapsulation 
efficiency  and  better  monodispersity  might  be  achieved  by  the  o/o 
emulsification-solvent evaporation method, depending on the amount 
of  drug  loading  used.  The  in  vitro  degradation  rate  of  all  the 
microspheres in pH 7.4 phosphate buffer solution showed first-order 
kinetics, and ranked in the order of  PLGA>PLA>PV microspheres.
5. Fernandez et al.,16 (2000) developed  a controlled release formulations 
of alachlor in ethyl cellulose. Microencapsulted alachlor should have 
reduced potential  for  leaching in the soil  while maintaining effective 
biological activity. Microspheres of alachlor were prepared using ethyl 
cellulose, according to the solvent evaporation method.
6. Michail Abainge et al.,17(2000) studied the sustained release nature of 
ofloxacin microspheres-to eradicate bacterial  biofilm associated with 
chronic  infections from sensitive  strains  of  bacteria-was  determined 
both in vitro  and in vivo.  Ofloxacin microspheres were prepared by 
emilsion solvent evaporation procedure using poly(glycolic acid-co-dl-
lactic acid)(PLGA) as the biodegradable polymer. The microspheres 
were characterized by scanning electron microscopy, in vitro release 
in an incubator, and in vivo release in the rat subcutaneous model. 
The microspheres were highly spherical with a very smooth surface.
7. Yang  et  al.,18 (2000)  studied  microencapsulation  of  aspirin  in  ethyl 
cellulose  was  in  a  surfactant-free,  water-in-oil  type  of 
emulsification/solvent  evaporation  process  using  non-toxic  solvents. 
Ethanol  was  used as  the dispersed phase and soybean oil  as  the 
continuous  phase.  The  addition  of  a  small  amount  of  non-solvent 
(water)  prior  to  the  emulsification  was  found  to  have  a  significant 
impact on the microencapsulation process. The addition of non-solvent 
also markedly changes the microsphere characteristics, resulting in a 
coarser surface and an increased release rate.
8. Vandelli et al.,19 (2001) proposed a new non-toxic cross linking agent, 
D.L-glyceraldehyde(GAL),  to  overcome  the  restriction  in  using 
crosslinked gelatin in the pharmaceutical field. Gelatin microspheres 
crosslinked with different concentrations of GAL (0.5, 1 or 2 % w/v) 
and for different time periods (1 or 24 h) were prepared. To evaluate 
the  pharmaceutical  properties,  an  antihypertensive  drug,  clonidine 
hydrochloride,  was  chosen  as  drug  model  and  loaded  into  the 
microspheres.
9. Perumal20 (2001)  proposed  a  method  to  prepare  modified  release 
microsphre of ibuprofen by emulsion solvent diffusion. The technique 
was  optimized  for  the  following  processing  variables:  the 
absence/presence of baffles in the reaction vessel, agitation rate and 
drying time. Thereafter, the influence of various formulation factors on 
the  microencapsulation  efficiency,  in  vitro  drug  release  and 
micromeritic  properties  was  examined.  The  variables  included  the 
methacrylic  polymer,  Eudragit  RS  100,  ibuprofen  content  and  the 
volume  of  ethanol  used  during  microencapsulation.  The  results 
obtained were then interpreted on a triangular phase diagram to map 
the region of microencapsulation, as well as those formulations that 
yielded suitable modified release ibuprofen microspheres.
10. Pérez-Martínez  et.al.,21  (2001) studied that the pesticide norfluazon 
has  been  microencapsulated  using  ethyl  cellulose  to  develop 
controlled-release formulations that decrease its mobility through the 
soil and protect it from photodegradation. Ethyl cellulose microspheres 
loaded  with  norfluazon  were  prepared  by  the  solvent-evaporation 
method.  To  obtain  the  microspheres,  certain  conditions 
(pesticide/polymer ratio, percentage of emulsifying agent and solvent) 
were varied. The shape and size of the microspheres obtained were 
studied by scanning electron microscopy. Other parameters, such as 
solids recovery, encapsulation efficiency and pesticide loading, were 
also  studied.  The  release  rate  of  norfluazon  from  the  different 
microspheres was slower than that of pure norfluazon. In particular, 
microspheres  obtained  with  o-xylene,  which  provided  the  largest 
diameter,  retarded  the  initial  release  of  the  pesticide  relative  to 
microspheres  obtained  with  chloroform,  or  to  pure  norfluazon. 
Moreover,  the  studies  showed  that  the  pesticide/polymer  ratio 
controlled the release of norfluazon, which was slower when this ratio 
was low. Release rates conformed to a generalized kinetic equation 
for a diffusion-controlled release mechanism, and the time taken for 
50%  of  the  active  ingredient  to  be  released  into  water,  t50,  was 
calculated.
11. Sajeev  et  al.,22 (2002) formulate  and  evaluate  microencapsulated 
controlled release preparations of diclofenac sodium (DFS) using di. 
eren proportions of ethyl  cellulose (EC) as the retardant material to 
extend  the  release.  The  formulated  microcapsules  were  then 
compressed into tablets to obtain controlled release oral formulations. 
Phase separation-coacervation  technique was  employed  to  prepare 
microcapsules  of  DFS  using  di.  erent  proportions  of  EC  in 
cyclohexane.  Physical  characteristics  of  microcapsules  and  their 
tablets,  in  vitro  release  pattern  of  the  designed microcapsules  and 
their tablets prepared from them were studied using USP dissolution 
apparatus (USP 2000) type 2 (paddle method) in triple distilled water. 
The prepared microcapsules were white, free ¯owing and spherical in 
shape,  with  the  particle  size  varying  from  49.94±52.72  mm.  The 
duration of DFS release from microcapsules was found to be directly 
proportional  to  the  proportion  of  EC  and,  thus,  coat  thickness.  All 
tablets were of good quality with respect to appearance, drug content 
uniformity,  hardness,  weight  variation,  friability  and  thickness 
uniformity. In vitro release study of the tabletted microcapsules in triple 
distilled  water  showed  zero  order  release  kinetics  and  extended 
release beyond 24 h. A good correlation was obtained between drug 
release (t60) and proportion of EC in the microcapsules. In the case of 
tabletted microcapsules,  very good correlation could be established 
between  t60,  proportion  of  EC,  weight  of  the  tablets  and  between 
release rate constant (K) and proportion of EC. All the formulations 
were highly stable and possessed reproducible release kinetics across 
the batches.
12.  Sinha et al.,23 (2004) proposed that Chitosan is a biodegradable natural 
polymer with great potential for pharmaceutical applications due to its 
biocompatibility, high charge density, non-toxicity and mucoadhesion. It 
has  been  shown  that  it  not  only  improves  the  dissolution  of  poorly 
soluble drugs but also exerts a significant effect on fat metabolism in 
the body. Gel formation can be obtained by interactions of chitosans 
with low molecular counterions such as polyphosphates, sulphates and 
crosslinking  with  glutaraldehyde.  This  gelling  property  of  chitosan 
allows a wide range of applications such as coating of pharmaceuticals 
and  food  products,  gel  entrapment  of  biochemicals,  plant  embryo, 
whole cells, microorganism and algae. This review is an insight into the 
exploitation of the various properties of chitosan to microencapsulate 
drugs.  Various techniques used for  preparing  chitosan microspheres 
and evaluation of  these microspheres has also been reviewed.  This 
review also includes the factors that affect the entrapment efficiency 
and release kinetics of drugs from chitosan microspheres.
13. Jiahui Hu et al.,1 (2004) Poor water solubility is an industry wide issue, 
especially  for  pharmaceutical  scientists  in  drug discovery  and drug 
development.  In  recent  years,  nanoparticle  engineering  processes 
have  become  promising  approaches  for  the  enhancement  of 
dissolution  rates  of  poorly  water  soluble  drugs.  Nanoparticle 
engineering enables manufacture of poorly water soluble drugs into 
nanoparticles  alone,  or  incorporation  with  a  combination  of 
pharmaceutical  excipients.  The  use  of  these  processes  has 
dramatically  improved  in  vitro  dissolution  rates  and  iv  vivo 
bioavailability  of  many  poorly  water  soluble  drugs.  This  review 
highlights several commercially or potentially commercially available 
nanoparticle engineering processes recently reported in the literature 
for increasing the dissolution properties of poorly water soluble drugs.
14. Chowdary  et al.,24 (2004) prepared ethyl  cellulose microspheres of 
glipizide  were  prepared by an industrially  feasible  emulsion-solvent 
evaporation technique and the microspheres were investigated. The 
microspheres are spherical, discrete and free-flowing. Encapsulation 
efficiency was in the range of 81-91 percent. Glipizide release from 
the microspheres was slow and diffusion controlled and extended over 
a period of 10 d and depended on core: coat ratio, wall thickness and 
size  of  the  microspheres.  Good linear  relationships  were  observed 
between  percent  coat,  wall  thickness  and  release  rate  of  the 
microspheres. In the in vivo, the microspheres produced a sustained 
hypoglycemic effect over 6 d in normal rabbits. These microspheres 
were found suitable for parenteral controlled release.
15. Yasunori  Sato  et  al.,25 (2004)  formulated  hollow  microspheres 
(microballoons) floatable in JPX III  No.1 solution as a dosage form 
characterized  by  excellent  buoyant  properties  in  the  stomach. 
Microballoons  were  prepared  by  the  emulsion  solvent  diffusion 
method utilizing enteric acrylic  polymers codissolved with  drug in a 
mixture of dichloromethane and ethanol. The release properties of five 
different  drugs  exhibiting  distinct  water  solubility  entrapped  within 
microballoons  were  investigated.  Buoyancy  of  the  microballoons 
decreased with increasing drug release rate. In the case of aspirin, 
salicylic  acid  and  ethoxybenzamide,  the  drug  release  profiles  of 
microballoons  proved  a  linear  relationships  by  Higuchi  plotting. 
However,  indomethacin and riboflavin release pfofiles did not follow 
the  Higuchi  equation.  When  the  loading  amount  of  riboflavin  was 
higher  than  the  solubility  in  the  admixture  of  dichloromethane  and 
ethanol, the drug release profiles of the microballoons displayed and 
initial burst release.Riboflavin crystals were released preferentially at 
the initial stage of the release test, which was attributable to the initial 
burst.  In  addition,  by  incorporating  a  polymer  such  as 
hydroxypropylmethylcellulose  within  the  shell  of  microballoons,  the 
release rate of riboflavin from the microballoons could be controlled 
while maintaining high buoyancy.
16. Martinac  et  al.,26 (2005)  Loratadine-loaded  microspheres  were 
prepared by spray-drying of dispersions, emulsions and suspensions 
differing  in  polymeric  composition  and  solvents  used.  composed 
microspheres were  obtained by spray-drying  of  two-phase systems 
composed of chitosan and ethylcellulose (EC). Microspheres differed 
in EC/CM weight ratio (0:1, 1:2 and 1:3) and in loratadine/polymers 
weight ratio (1:6 and 1:8). Tensile studies showed that both, EC/CM 
ratio and the type of spray-dried system influenced the bioadhesive 
properties of the microspheres in a way that the microspheres with 
higher  chitosan  content  were  more  bioadhesive  and  microspheres 
prepared  from  suspensions  were  more  bioadhesive  than  those 
prepared  from  emulsions,  regardless  of  the  same  polymeric 
composition.
17. Zohra Zili et al.,2 (2005) prepared poly-ε-caprolactone nanospheres and 
nanocapsules of Griseofulvin by nanoprecipitation and to characterize 
them.  Nanoparticles  of  Griseofulvin  were  obtained  with  high 
encapsulation efficiency. The particle size was about 250-326 nm for 
nanospheres and 390-400 nm for nanocapsules. The dissolution rate of 
Griseofulvin  nanoparticles  was  higher  than  that  of  micronized 
Griseofulvin  therefore  recourse  to  nanoencapsuation  of  Griseofulvin 
should  enhance  its  bioavailability  and  possibly  its  efficiency  for  the 
treatment of dermatomycosis.
 18. Jong et al.,27 (2006) prepared hydrophobically modified glycol chitosan 
(HGC) nanopaticles as a carrier for paclitaxel.  HGC conjugates were 
prepared  by  chemically  linking  5β-cholanic  acid  to  glycol  chitosan 
chains using 1-ethyl-3-(3-dimethylaminopropyl)-carbodimide chemistry. 
Paclitaxel was efficiently loaded into HGC nanoparticles up to 10 wt% 
using  dialysis  method.  The  pacelitaxel-loaded  HGC  (PTX-HGC) 
nanoparticles were 400nm in diameter and were stable in PBS for 10 
days. These PTX-HGC nanoparticles also showed sustained release of 
the incorporated of paclitaxel (80% of the loaded dose was released in 
8  days  at  37ºC in  PBS).  Finally,  PTX  was  less  toxic  to  the  tumor-
bearing  mice  when  formulated  in  HGC  nanopaticles  than  when 
formulated with Cremophor EL.
19. Kocbek et al.,28 (2006) developed a method to enhance the dissolution 
of  poorly  soluble  drugs  by  preparing  nanosuspensions.  The  melt 
emulsification  method  traditionally  used  to  prepare  solid  lipid 
nanoparticles  was  adapted  to  produce  drug  nanosuspensions.  The 
method  was  evaluated  in  comparison  with  the  well  known  solvent 
diffusion  process  for  ibuprofen  as  a  model  drug.  Control  of  the 
preparation  variables  (stabilizers,  drug  content,  homogenization 
procedure  and  cooling  conditions)  allowed  formation  of 
nanosuspensions  with  diameters  less  than  100  nm.  The  major 
advantage of the melt emulsification method over the solvent diffusion 
method  is  the  avoidance  of  organic  solvents  during  production, 
although the mean particle size is slightly greater. The formulation of 
ibuprofen as a nanosuspension, either in the form of lyophilized powder 
of granules, was very successful in enhancing the dissolution rate when 
compared to the micronized drug. The increase in vitro dissolution rate 
may favorably affect bioavailability and improve safety for the patient by 
decreasing gastric irritancy.
 20. Wong SM et al.,29 (2006)The slow dissolution rate exhibited by poorly 
water-soluble  drugs  is  a  major  challenge  in  the  drug  development 
process.  Following  oral  administration,  drugs  with  slow  dissolution 
rates generally show erratic and incomplete absoption which may lead 
to  therapeutic  failure.  The  aim  of  this  study  was  to  improve  the 
dissolution  rate  and  subsequently  the  oral  absoption  and 
bioavailability of  a model  poorly water  soluble drugs. Microparticles 
containing  the  model  drug  (Griseofulvin)  were  produced  by  spray 
drying the drug in the absence/presence of a hydrophilic surfactant. 
Poloxamer 407 was chosen as the hydrophilic surfactant to improve 
the particle wetting and hence the dissolution rate. The spray dried 
particles were characterized and in vitro dissolution studies and in vivo 
absorption studies were carried out. The results obtained showed that 
the dissolution rate and absolute oral bioavailability of the spray dried 
Griseofulvin/poloxamer  407  particles  were  significantly  increased 
compared  to  the  control.  Although  spray  drying  Griseofulvin  alone 
increased  the  drugs  in  vitro  dissolution  rate,  no  significant 
improvement  was  seen  in  the  absolute  oral  bioavailability  when 
compared  to  the  control.  Therefore,  it  is  believed  that  the  better 
wetting  characteristics  conferred  by  the  hydrophilic  surfactant  was 
responsible  for  the  enhanced  dissolution  rate  and  absolute  oral 
bioavailability of the model drug.
21. Gavini  et  al.,30 (2006)  studied  the  nasal  administration  of 
Carbamazepine  (CBZ)  has  been  studied  using  microspheres 
constituted by chitosan hydrochloride(CH) or chitosan glutamate(CG). 
The microspheres were produced using a spray-drying technique and 
characterized  in  terms  of  morphology  (scanning  electron 
microscopy(SEM), drug content, particle size(laser diffraction method) 
and  thermal  behavior  (DSC).  In  vitro  drug  release  studies  were 
performed in phosphate buffer(pH 7.0). In vivo tests were carried out in 
sheep using the microparticle containing chitosan glutamate, chosen on 
the basis of the results of in vitro studies.
III. EXPERIMENTAL
3.1 Materials used
# Griseofulvin
Gift sample from CFL and Wallace pharmaceuticals  
# Chitosan
Fluca Biochemicals 
# Ethylcellulose
S d fine-chem Ltd.
# Petroleum ether
Qualigens fine chemicals
# Light liquid paraffin
Spectrum reagent and chemicals
# Acetic acid glacial
S d fine-chem limited
# Acetone
Qualigens fine chemicals
# Tween- 80
Indian research products
# Methanol
Qualigens fine chemicals
# Polyvinyl alcohol
Loba chemie Pvt. Ltd.
# Chloroform
Qualigens fine chemicals
# Glutaraldehyde
Kemphasol
3.2. Instruments and equipments used
# UV Visible spectrophotometer
Shimadzu 1400 double beam
# Electronic balance
Denver instrument XS – 210
# Dissolution test apparatus USP XXIV
M/s. Tab Machines, Mumbai
# IR – hydraulic pellet press
Kimaya Engineers (Type – WT, SR No.330) India
# Magnetic stirrer
Remi motors
  3.3 Methods
Method I  - Preparation of  Chitosan microparticles by cross-linking 
method.
Method II- Preparation  of  Ethyl  cellulose  microarticles  by  solvent 
evaporation method.
METHOD- I
PREPARATION OF CHITOSAN MICROPARTICLES BY CROSS-LINKING 
METHOD 13:
About 200 mg of chitosan was dissolved in 10 ml of 5 % acetic acid 
solution. Mix the various concentrations of drug (Griseofulvin) in the polymer 
solution and this whole was slowly added to 60 ml of the suspension medium 
containing  mineral  oil/  petroleum  ether  (60/40,  v/v)  mixture  and  1  ml  of 
Tween-80 as an emulsifier. The suspension medium was stirred at 2000 rpm 
for 10 minute and 1 ml of gltaraldehyde was added into the medium and 
stirring  continued.  After  1  and  2  hours  add  0.5  ml  of  glutaraldehyde, 
respectively, were added into the suspension medium and stirring continued. 
At the end of 3 hour, stirring was stopped and the chitosan microspheres 
were  washed  several  times  with  petroleum ether,  5% sodium  bisulphate 
solution  and acetone,  (consecutively)  and then were  dried  in  an  oven at 
65°C.
METHOD-II
PREPARATION  OF  ETHYLCELLULOSE  MICROPARTICLES  BY 
SOLVENT EVAPORATION METHOD 16:
About  200  mg  of  ethyl  cellulose  was  dissolved  in  20  ml  of 
dichloromehane  (DCM)  or  chloroform.  Different  amounts  of  Drug 
(Griseofulvin)  were  dissolved  in  this  polymer  solution  at  30°C.  The 
drug/polymer solution was then added drop-wise to a dispersion phase (200 
ml)  consisting  PVA  solution,  under  stirring.  After  2  hours  of  stirring,  the 
products were filtered, washed with 1 liter of distilled water and air-dried at 
room temperature.
Table:3 Formulation Code For Chitosan Preparations
FORMULATION-
CODE
DRUG:POLYMER
RATIO
POLYMER
NAME
GLUTARAL-
DEHYDE
(ML)
C1G1
10:200
CHITOSAN
1
C1G2 2
C1G3 3
C2G1
20:200 CHITOSAN
1
C2G2 2
C2G3 3
C3G1
30:200 CHITOSAN
1
C3G2 2
C3G3 3
Table: 4 Formulation Code For Ethylcellulose Preparations
FORMULATION-
CODE
DRUG:POLYMER
RATIO
POLYMER
NAME
POLYVINYL
ALCOHOL
(%)
E1P1
10:200
ETHYL-
CELLULOSE
0.15
E1P2 0.20
E1P3 0.25
E2P1
20:200
ETHYL-
CELLULOSE
0.15
E2P2 0.20
E2P3 0.25
E3P1
30:200
ETHYL-
CELLULOSE
0.15
E3P2 0.20
E3P3 0.25
Abbreviations:
G           - Glutaraldehyde
PVA      - Polyvinyl alcohol
IV. STUDIES ON DRUG DELIVERY USING 
GRISEOFULVIN WITH CHITOSAN AND ETHYLCELLULOSE 
POLYMERS
4.1. Preformulation studies
(i) Interaction study
Infrared (IR) absorption spectroscopy:
To investigate  any possible  interactions  between  the  drug and the 
polymers, the IR spectra of pure drug Grieofulvin and its physical mixtures 
(1:1) with Chitosan and Ethylcellulose were carried out using Shimadzu IR-
470 spectrophotometer (Tokyo, Japan). The samples were prepared as KBr 
disks compressed under a pressure of 6 ton/nm2. The wave length selected 
ranged between 400- 4000 cm-1 in a Perkin Elmer FTIR spectrophotometer. 
The IR spectrum of the physical mixture was compared with those of pure 
drug and polymers  and matching was done to  detect  any appearance or 
disappearance of peaks.
Procedure:
First  a pinch of drug was added to the dried KBr, and triturated in 
mortar. The pellet was made by using pellet plate technique, and kept in IR 
chamber and scanned to get the spectra. The same procedure was followed 
for the combination of drug-polymer too.
By  comparing  the  IR  spectrum  of  drug  and  drug-polymer 
combinations, it was inferred that in both cases the characteristic peaks were 
obtained at  same wave  numbers.  So from this  it  was  concluded that  no 
structural  changes  had  occurred  for  the  drug  when  combined  with  the 
polymers. 
Fig :4 IR Spectra of Griseofulvin- pure sample
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FIig:5 IR Spectra of Chitosan- pure sample
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Fig: 6 IR Spectra of ethyl cellulose- pure sample
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Fig :7 IR Spectra of Griseofulvin with Chitosan
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Fig :8 IR Spectra of Griseofulvin with Ethyl cellulose
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4.2. Standard graph of Griseofulvin
Preparation of stock solution:
100  mg  of  Griseofulvin  dissolved  in  100  ml  of  pH  7.4 
phosphate buffer to get a concentration of 1000 µg/ml.
From this  take 10 ml and made up to 100 ml with  pH 7.4 
phosphate buffer to get a concentration of solution 100 µg/ml.
Preparation of various concentrations of drug solution
1. 0.05 ml of the stock solution was made up to 10 ml with 
pH 7.4 phosphate buffer to give 5 µg/ml.
2. 1 ml of the stock solution was made up to 10 ml with pH 
7.4 phosphate buffer to give 10 µg/ml.
3. 1.5 ml of the stock solution was made up to 10 ml with pH 
7.4 phosphate buffer to give 15 µg/ml.
4. 2.0 ml of the stock solution was made up to 10 ml with pH 
7.4 phosphate buffer to give 20 µg/ml.
5. 2.5 ml of the stock solution was made up to 10 ml with pH 
7.4 phosphate buffer to give 25 µg/ml.
6. 3.5 ml of the stock solution was made up to 10 ml with pH 
7.4 phosphate buffer to give 30 µg/ml.
Procedure:
Various concentrations of Griseofulvin (5, 10, 15, 20, 25 and 
30  µg/ml) were prepared as mentioned above. Absorbance of the 
solution was measured against reagent blank at 291 nm using UV 
Spectro photo meter. A standard graph between concentration Vs 
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absorbance was plotted. A straight line passing through origin was 
obtained.
Table: 5 Calibration Data for the Estimation of Griseofulvin (5-30 
µ g/ml)
S.No Concentration in µ g/ml Absorbance at 291 nm
1 0 0.0000
2 5 0.1350
3 10 0.2720
4 15 0.4100
5 20 0.5250
6 25 0.6650
7 30 0.7900
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Fig 9 Calibration Data Curve For the Estimation Of Griseofulvin (5-30 µ g/ml)
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4.3. Drug content analysis
UV spectrophotometric  method was  employed  to  verify  the 
presence of drug in the micropartilces. Crush the microparticles and 
the drug was extracted with phosphate buffer 7.4 and absorbance 
was measured using UV spectrophotometer at 291nm. The amount 
of Griseofulvin in the micropartilces was estimated with the help of 
standard graph. A study was performed in  the percentage yield and 
percentage encapsulation efficiency.
Table:6 Amount of Drug Loaded in Chitosan microparticles
DRUG: POLYMER 
(mg)
AMOUNT OF DRUG LOADED 
1 ml G 2 ml G 3 ml G
10 : 200 5.464 mg 5.760 mg 5.869 mg
20 : 200 11.832 mg 12.48 mg 13.02 mg
30 : 200 24.973 mg 25.172 mg 26.88 mg
Fig:10
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Table:7 Encapsulatin Efficiency Of Chitosan Microparticles
DRUG:POLYMER (mg) PERCENTAGE DRUG LOADING 1 ml G 2 ml G 3 ml G
10 : 200 54.64 % 57.60 % 58.69 %
20 : 200 59.16 % 62.4 % 65.1 %
30 : 200 83.24 % 83.90 % 89.6 %
Fig:11
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Table:8  Percentage Yield Of Chitosan Microparticles
DRUG:POLYMER (mg) PERCENTAGE YIELD 1 ml G 2 ml G 3 ml G
10 : 200 94.28 % 95.24 % 95.71 %
20 : 200 92.72 % 94.54% 95.45 %
30 : 200 96.08 % 94.35 % 97.39 %
Fig:12
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Table:9 Amount of Drug Loaded in Ethylcellulose microparticles
DRUG: POLYMER 
(mg)
AMOUNT OF DRUG LOADED
0.15 %PVA 0.20 % PVA 0.25 % PVA
10:200 4.961 mg 4.29 mg 3.48 mg
20:200 12.14 mg 10.08 mg 7.98 mg
30:200 19.79 mg 18.04 mg 15.09 mg
Fig:13
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Table:10 Encapsulatin Efficiency Of Ethylcellulose 
Microparticles
DRUG: POLYMER 
(mg)
PERCENTAGE DRUG LOADING
0.15 % PVA 0.20 % PVA 0.25 % PVA
10:200 49.61 % 42.9 % 34.8 %
20:200 60.7 % 50.4 % 39.9 %
30:200 65.96 % 60.13 % 50.3 %
Fig:14
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Table:11Percentage  Yield  Of  Ethylcellulose 
Microparticles
DRUG:POLYMER (mg) PERCENTAGE YIELD0.15 % PVA 0.20 % PVA 0.25 % PVA
10: 200 97.62 % 93.80 % 95.23 %
20: 200 96.81 % 95.45 % 95.45 %
30: 200 94.78 % 95.65 % 96.52 %
Fig:15
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4.4  Determination  of  size  and  shape  of  the 
microparticles 
(i)  Determination  of  shape  and  size  of  microparticles  by 
scanning electron microscope
The surface morphology and internal  texture of griseofulvin 
mincrosparticles were observed by a scanning electron microscope 
(SEM).  SEM  photographs  were  taken  on  Jsm  6400  scanning 
electron  microscope  at  3K  magnification  at  room  temperature. 
Before scanning the microparticles were sputtered with gold to make 
the  surface  conductive.  The  figures  shows  that  the  particles  are 
spherical enough having rough surface.
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Fig:16 Scanning electron picture of chitosan micropartilce
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Fig:17 Scanning electron picture of ethyl cellulose 
microsparticle
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(ii) Measurement of particle size determination of miroparticles 
by optical microscopic method:
First clean the microscope and place it in proper place where 
light is suitable for projection. Fix the eye-piece in microscope with 
micrometer.  Calibrate  the  eye-piece  micrometer  with  a  standard 
stage  micrometer.  Mount  the  sample  on  the  plain  slide.  Then 
measure  the  size  of  the  particles  with  the  help  of  eye-piece 
micrometer. Count accurately 200 particles.
Arithmetic mean = Σnd / Σn
Table:12 Calibration of Eye Piece  Micrometer
STAGE MICROMETER 0 15 21 45 60
EYEPIECE MICROMETER 0 10 14 30 40
Particle Size Determination by Optical Microscopic Method 
TABLE:13
The Arithmetic Mean of Particle Size – C1G1 = 165.37
C1G2 = 167.32
C1G3 = 169.12
TABLE:14
The Arithmetic Mean of Particle Size – C2G1 = 175.8
C2G2 = 178.5
C2G3 = 179.6
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TABLE:15
The Arithmetic Mean of Particle Size – C3G1 = 189.75
C3G2 = 191.62
C3G3 = 200.62
TABLE:16
The Arithmetic Mean of Particle Size – E1P1 = 339
E1P2 = 340.5
E1P3 = 345
TABLE:17
The Arithmetic Mean of Particle Size – E2P1 = 348
E2P2 = 349.5
E2P3 = 352.5
TABLE:18
The Arithmetic Mean of Particle Size – E3P1 = 378
E3P2 = 384.75
E3P3 = 399
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4.5  In vitro drug release studies:
Procedure: 
Release  of  Griseofulvin  from  microspheres  was  studied  in 
phosphate buffer 7.4 pH (100 ml) using a USP XXI/XXII dissolution 
rate apparatus, with a paddle rotating at a rate of 100 RPM and at 
37±0.5°C, samples are with drawn through a syringe at different time 
interval  and  were  assayed  at  291  nm  for  Griseofulvin  using  UV 
visible  double  beam  spectrophotometer.  The  drug  release 
experiment was conducted in triplicate.
Calculation:
To calculate the actual percentage release, it is necessary to 
calculate  the  theoretical  release  of  drug.  It  can  be  calculated  by 
using the general formula,
Theoratical  release  =  (Total  amount  of  drug  loaded  in  1  mg  of 
microparticles  )  ×   (  Amount  of  microparticles  taken  for  in  vitro 
studies )
The  exact  percentage  relese  of  drug  can  be  obtained  by  the 
following general formula:
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IN VITRO DISSOLUTION PROFILE IN PH 7.4
TABLE:19
TIME IN Hrs PERCENTAGE RELEASE OF GRISEOFULVIN ON 
VARIOUS CONCENTRATIONS OF CHITOSAN  (%)
C1G1 C1G2 C1G3
2 27.18 23.5 18.09
4 29.32 26.42 21.74
6 30.54 27.79 22.68
8 34.76 32.3 25.27
10 39.19 34.53 27.4
12 42.65 36.02 31.34
24 51.74 43.41 38.26
FIG:18
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TABLE:20
TIME IN Hrs
PERCENTAGE RELEASE GRISEOFULVIN ON 
VARIOUS CONCENTRATIONS OF CHITOSAN (%)
C2G1 C2G2 C2G3
2 31.17 29.51 23.63
4 33.71 30.55 24.31
6 36.82 32.1 27.39
8 39.32 35.41 28.08
10 43.24 36.45 31.50
12 45.30 39.58 32.87
24 52.19 46.87 39.72
FIG:19
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TABLE:21
FIG:20
CHITOSAN 30:200
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TABLE:22
TIME IN Hrs
PERCENTAGE RELEASE GRISEOFULVIN ON 
VARIOUS CONCENTRATIONS OF 
ETHYLCELLULOSE (%)
E1P1 E1P2 E1P3
2 8.2 6.31 2.5
4 9.71 9.74 4.17
6 13.18 12.56 5.82
8 15.4 16.18 9.31
10 18.94 17.87 12.65
12 20.37 19.69 13.08
24 27.17 25.27 18.17
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FIG:21
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TABLE:23
TIME IN Hrs
PERCENTAGE RELEASE GRISEOFULVIN ON VARIOUS 
CONCENTRATIONS OF ETHYLCELLULOSE (%)
E2P1 E2P2 E2P3
2 9.17 7.63 3.63
4 13.08 8.31 5.11
6 17.03 11.96 6.24
8 18.81 14.40 10.6
10 21.4 18.07 12.82
12 24.62 21.61 13.41
24 33.91 29.54 23.05
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FIG:22
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TABLE:24
TIME IN Hrs
PERCENTAGE RELEASE GRISEOFULVIN ON 
VARIOUS CONCENTRATIONS OF 
ETHYLCELLULOSE (%)
E3P1 E3P2 E3P3
2 11.61 8.38 5.17
4 12.36 10.09 6.23
6 15.04 12.54 10.48
8 17.09 13.65 11.63
10 20.42 16.76 14.74
12 23.18 21.43 15.79
24 42.86 30.18 24.52
FIG:23
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RESULTS AND DISCUSSIONS
CHITOSAN
1) IR spectra of chitosan microparticles:
An IR spectrum of the drug-polymer mixture was taken 
to  study  and  check  the  drug-polymer  interaction.  The 
spectrum revealed no interaction.
2) Yield of the product:
An  average  product  yield  for  the  formulation  10:200 
(drug: polymer) was 95.07%, 20:200 was 94.24% and 30:200 
was 95.94%.
3) Preparation of chitosan microparticles:
Chitosan microparticles were prepared by the chemical 
cross-linking  method.  The  batch  of  microparticles  was 
subjected to SEM analysis for their size determination. The 
size range was found to be between 165.37µm – 200.62µm.
4) Study on the encapsulation efficiency of Griseofulvin into 
the microparticles:
To study the maximum amount of drug, which could be 
incorporated  into  the  microparticles,  different  batches  of 
microparticles  were  prepared  containing  10mg,  20mg,  and 
30mg  of  the  drug  with  various  concentrations  of  the 
Gluteraldehyde  amount.  The  amount  of  polymer  used  was 
kept  as  constant.  The  drug  encapsulation  efficiency  of  the 
microparticles containing 10mg, 20mg and 30mg of drug was 
found  to  be  in  average  of  56.97%,  62.22%  and  85.58% 
respectively.  So  30  mg  of  drug  Griseofulvin  may  be 
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considered  as  the  ideal  concentration  to  load  into  the 
prepared chitosan microparticles.
To  estimate  the  amount  of  drug  bound  to 
microparticles,  the chitosan microparticles containing 10mg, 
20mg and 30mg of the drug was subjected to UV analysis and 
the calculation revealed that an average of 5.75mg, 12.44mg 
and 25.675mg of drug bound to the microparticles
5) Study  of   in  vitro  release  from  prepared  chitosan 
microparticles:
The release studies were carried out for 24 hours. In the first 
two  hours  an  average  of  22.92%  for  10:200  (drug:  polymer), 
28.10% for 20:200 and 33.87% for 30:200 were released. After the 
second hour onwards microparticles released the drug in a sustained 
manner.
ETHYLCELLULOSE
1) IR spectra of ethylcellulose microparticles:
IR spectra of the drug-polymer mixture were taken to 
study and check the drug-polymer interaction. The spectrum 
revealed no interaction.
2) Yield of the product:
An  average  product  yield  for  the  formulation  10:200 
(drug: polymer) was 95.55%, 20:200 was 95.90% and 30:200 
was 95.65%.
3) Preparation of ethylcellulose microparticles:
Ethylcellulose  microparticles  were  prepared  by  the 
solvent evaporation method. The batch of microparticles was 
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subjected to SEM analysis for their size determination. The 
size range was found to be between 339µm – 399µm.
4) Study on the encapsulation efficiency of Griseofulvin into 
the microparticles:
To study the maximum amount of drug, which could be 
incorporated  into  the  microparticles,  different  batches  of 
microparticles  were  prepared  containing  10mg,  20mg,  and 
30mg of the drug with various concentrations of the polyvinyl 
alcohol  amount.  The amount of  polymer  used was kept  as 
constant.  The  drug  encapsulation  efficiency  of  the 
microparticles containing 10mg, 20mg and 30mg of drug was 
found  to  be  in  average  of  42.44%,  50.3%  and  58.79% 
respectively.  So  30  mg  of  drug  Griseofulvin  may  be 
considered  as  the  ideal  concentration  to  load  into  the 
prepared ethylcellulose microparticles.
To  estimate  the  amount  of  drug  bound  to 
microparticles,  the  ethylcellulose  microparticles  containing 
10mg,  20mg  and  30mg  of  the  drug  was  subjected  to  UV 
analysis  and  the  calculation  revealed  that  an  average  of 
4.24mg,  10.06mg  and  17.64mg  of  drug  bound  to  the 
microparticles.
5) Study  of  in  vitro  release  from  prepared  ethylcellulose 
microparticles:
The  release  study  clearly  shows  that  ethylcellulose 
releasing the drug in a sustained manner.
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SUMMARY AND CONCLUSION
SUMMARY
The preparation and evaluation of  microparticles containing 
Griseofulvlin  using  chitosan  and  ethyl  cellulose  were  compared 
under the following headings.
1) Estimation of the drug encapsulation efficiency of chitosan 
microparticles an ethyl cellulose microparticles:
 Different batches containing various concentrations of drug 
and  same  concentration  of  the  polymers  were  prepared  and 
estimated  for  the  amount  of  drug  loaded  in  each  batch.  A 
comparative result revealed that may be a maximum of 30 mg could 
be incorporated in both polymers.
 A  comparison  of  the  drug  binding  capacity  of  the 
microparticles containing two polymers showed that the drug bound 
to chitosan was greater than ethyl cellulose.
2) In vitro release studies:
The release pattern of the chitosan microparticles revealed a 
faster  release  (28.29%)  in  the  first  two  hours  (because  of  burst 
release) but ethyl cellulose showed a sustained release through the 
period.
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CONCLUSTION:
From  the  results  obtained  it  is  evident  that  microparticles 
containing  Griseofulvin  prepared  using  chitosan  exhibited  better 
yield, drug encapsulation and fast release when compared to ethyl 
cellulose microparticles. The fast release of chitosan microparticle 
may  be  due  to  the  chemical  cross-linking  of  the  polymer 
glutaraldehyde. 
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